Khaja M, Torchon F, Millerman K. A rare case of sorafenib-induced severe hyponatremia.
SAGE Open Med Case Rep 2019;
7:2050313X19846048. [PMID:
31065359 PMCID:
PMC6488774 DOI:
10.1177/2050313x19846048]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Accepted: 04/03/2019] [Indexed: 12/21/2022] Open
Abstract
Background:
Sorafenib is an anti-angiogenic tyrosine kinase inhibitor used to treat
patients with renal cell cancer and advanced hepatocellular cancer. Common
adverse effects of sorafenib are rash, diarrhea, nausea, and abnormal liver
function test and hand-foot syndrome.
Case presentation:
Here, we present a case of a 90-year-old male who was prescribed sorafenib
after being diagnosed with hepatocellular cancer. At 1 week after sorafenib
initiation, he was admitted to the emergency room for an evaluation of
weakness. The patient had hyponatremia, a common electrolyte abnormality
seen in cancer patients. His hyponatremia improved when the sorafenib was
stopped, suggesting that this was a rare case of hyponatremia induced by
sorafenib.
Conclusion:
Although sorafenib is used in the treatment of hepatocellular cancer, it can
cause life-threatening complication such as hyponatremia. Early
identification of the cause of hyponatremia can prevent serious adverse
event.
Collapse